A total of 354 patients with malignant tumors（74 cases of cervical cancer， 65 cases of lung cancer， 55 cases of ovarian cancer， 50 cases of colorectal cancer， 43 cases of gastric cancer， 35 cases of esophageal cancer and 32 cases of pancreatic cancer） were selected as tumor group and divided into early stage （Ⅰ-Ⅱ） and late stage （Ⅲ-Ⅳ） tumor groups according to TNM stage. At the same time， 100 healthy patients were selected as control group. The prothrombin time （PT）， activated partial thromboplastin time （APTT）， thrombin time （TT），fibrinogen （FIB）， D-dimer （D-Dimer）， fibrin or fibrinogen degradation products （FDP）， antithrombin （AT）， platelet count and NLR of the subjects in various groups were compared and analyzed.

Compared with control group， PT in early and late stage tumor groups were prolonged （P<0.01）， APTT were shortened （P<0.05 or P<0.01）， and FIB， D-Dimer， FDP levels and NLR were all increased （P<0.01）；compared with control group， TT of the patients in late tumor group was shortened （P<0.05）， AT was decreased （P<0.05）， and platelet count was increased （P<0.05）；compared with early stage tumor group， PT of the patients in late tumor group was prolonged （P<0.01）， TT was shortened （P<0.01）， and FIB， D-Dimer， FDP levels and NLR were increased （P<0.01）.Compared with control group， PT of the patients in all tumor groups were prolonged （P<0.05 or P<0.01）， APTT were shortened in different types of tumor groups except esophageal cancer （P<0.05 or P<0.01）， TT of the patients with lung cancer， ovarian cancer， and esophageal cancer were shortened（P<0.05 or P<0.01）， FIB， D-Dimer and FDP in all tumor groups were increased（P<0.05 or P<0.01）， AT of the patients with colorectal cancer， esophageal cancer， and pancreatic cancer were decreased （P<0.05）， the platelet count of the patients with advanced ovarian cancer was increased （P<0.01）， and NLR in all tumor groups were increased（P<0.05 or P<0.01）.

In the patients with malignant tumors before treatment， the main indicators of peripheral blood are shortened APTT， increased FIB and D-Dimer levels and NLR， and the patients with advanced tumors also show increased platelet count and decreased AT， indicating that tumor patients have disorder of hemostasis and coagulation function and are prone to thrombotic events.